ReP USP - Resultado da busca

Artigo de periodico
Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction (2022)
Docherty, Kieran F; Ogunniyi, Modele O; Anand, Inder S; Desai, Akshay S; Diez, Mirta; Howlett, Jonathan G; Nicolau, Jose Carlos ; O'meara, Eileen; Verma, Subodh; Inzucchi, Silvio E
Source: Jacc-heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS, MORTALIDADE HOSPITALAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, v. 10, n. 1, p. 52-64, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2021.08.006. Acesso em: 18 nov. 2024.
APA
Docherty, K. F., Ogunniyi, M. O., Anand, I. S., Desai, A. S., Diez, M., Howlett, J. G., et al. (2022). Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction. Jacc-heart failure, 10( 1), 52-64. doi:10.1016/j.jchf.2021.08.006
NLM
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Vancouver
Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'meara E, Verma S, Inzucchi SE. Efficacy of dapagliflozin in black versus white patients with heart failure and reduced ejection fraction [Internet]. Jacc-heart failure. 2022 ; 10( 1): 52-64.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.jchf.2021.08.006
Artigo de periodico
Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry (2022)
Russo, Juan J; Yan, Andrew T; Pocock, Stuart J; Brieger, David; Owen, Ruth; Sundell, Karolina Andersson; Bagai, Akshay; Granger, Christopher B; Cohen, Mauricio G; Nicolau, Jose Carlos
Source: Journal of cardiology. Unidade: FM
Subjects: VASOS CORONÁRIOS, INFARTO DO MIOCÁRDIO, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RUSSO, Juan J et al. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry. Journal of cardiology, v. 79, n. 4, p. 522-529, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.jjcc.2021.10.024. Acesso em: 18 nov. 2024.
APA
Russo, J. J., Yan, A. T., Pocock, S. J., Brieger, D., Owen, R., Sundell, K. A., et al. (2022). Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry. Journal of cardiology, 79( 4), 522-529. doi:10.1016/j.jjcc.2021.10.024
NLM
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, Bagai A, Granger CB, Cohen MG, Nicolau JC. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry [Internet]. Journal of cardiology. 2022 ; 79( 4): 522-529.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.jjcc.2021.10.024
Vancouver
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, Bagai A, Granger CB, Cohen MG, Nicolau JC. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: insights from the TIGRIS registry [Internet]. Journal of cardiology. 2022 ; 79( 4): 522-529.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.jjcc.2021.10.024
Artigo de periodico
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial (2021)
Butt, Jawad H; Nicolau, Jose Carlos ; Verma, Subodh; Docherty, Kieran F; Petrie, Mark C; Inzucchi, Silvio E; Schou, Morten; Kosiborod, Mikhail N; Langkilde, Anna Maria; Martinez, Felipe A
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, GLICOSÍDEOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H et al. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, v. 23, n. 4, p. 601-613, 2021Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2124. Acesso em: 18 nov. 2024.
APA
Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., et al. (2021). Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, 23( 4), 601-613. doi:10.1002/ejhf.2124
NLM
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1002/ejhf.2124
Vancouver
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1002/ejhf.2124
Artigo de periodico
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes (2020)
Petrie, Mark C; Verma, Subodh; Docherty, Kieran F; Inzucchi, Silvio E; Anand, Inder; Belohlavek, Jan; Boehm, Michael; Chiang, Chern-En; Chopra, Vijay K.; Nicolau, José Carlos
Source: Jama-journal of the american medical association. Unidade: FM
Subjects: DIABETES MELLITUS, MÉTODO DUPLO-CEGO, HEMOGLOBINAS, INSUFICIÊNCIA CARDÍACA, FÁRMACOS (METABOLISMO E NUTRIÇÃO), PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PETRIE, Mark C et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, v. 323, n. 14, p. 1353-1368, 2020Tradução . . Disponível em: https://doi.org/10.1001/jama.2020.1906. Acesso em: 18 nov. 2024.
APA
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlavek, J., et al. (2020). Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, 323( 14), 1353-1368. doi:10.1001/jama.2020.1906
NLM
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1001/jama.2020.1906
Vancouver
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1001/jama.2020.1906
Artigo de periodico
Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference (2020)
Ostermann, Marlies; Bellomo, Rinaldo; Burdmann, Emmanuel de Almeida ; Doi, Kent; Endre, Zoltan H; Goldstein, Stuart L; Kane-Gill, Sandra L; Liu, Kathleen D; Prowle, John R; Shaw, Andrew D
Source: Kidney international. Unidade: FM
Assunto: INSUFICIÊNCIA RENAL AGUDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OSTERMANN, Marlies et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney international, v. 98, n. 2, p. 294-309, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.kint.2020.04.020. Acesso em: 18 nov. 2024.
APA
Ostermann, M., Bellomo, R., Burdmann, E. de A., Doi, K., Endre, Z. H., Goldstein, S. L., et al. (2020). Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney international, 98( 2), 294-309. doi:10.1016/j.kint.2020.04.020
NLM
Ostermann M, Bellomo R, Burdmann E de A, Doi K, Endre ZH, Goldstein SL, Kane-Gill SL, Liu KD, Prowle JR, Shaw AD. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference [Internet]. Kidney international. 2020 ; 98( 2): 294-309.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.kint.2020.04.020
Vancouver
Ostermann M, Bellomo R, Burdmann E de A, Doi K, Endre ZH, Goldstein SL, Kane-Gill SL, Liu KD, Prowle JR, Shaw AD. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference [Internet]. Kidney international. 2020 ; 98( 2): 294-309.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.kint.2020.04.020
Artigo de periodico
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial (2020)
Kosiborod, Mikhail N ; Jhund, Pardeep S; Docherty, Kieran F; Diez, Mirta; Petrie, Mark C; Verma, Subodh; Nicolau, Jose Carlos ; Merkely, Bela; Kitakaze, Masafumi; Demets, David L
Source: Circulation. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, QUALIDADE DE VIDA, BIOMARCADORES, HIDROCARBONOS AROMÁTICOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOSIBOROD, Mikhail N et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, v. 141, n. 2, p. 90-99, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044138. Acesso em: 18 nov. 2024.
APA
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., et al. (2020). Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, 141( 2), 90-99. doi:10.1161/CIRCULATIONAHA.119.044138
NLM
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Vancouver
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF (2020)
Martinez, Felipe A; Serenelli, Matteo; Nicolau, Jose Carlos ; Petrie, Mark C; Chiang, Chern-En; Tereshchenko, Sergey; Solomon, Scott D; Inzucchi, Silvio E; Kober, Lars; Kosiborod, Mikhail N
Source: Circulation. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, HIDROCARBONOS AROMÁTICOS, FATORES ETÁRIOS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINEZ, Felipe A et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, v. 141, n. 2, p. 100-111, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044133. Acesso em: 18 nov. 2024.
APA
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C. -E., Tereshchenko, S., et al. (2020). Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, 141( 2), 100-111. doi:10.1161/CIRCULATIONAHA.119.044133
NLM
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Vancouver
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Artigo de periodico
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Stein, Evan A.; Hovingh, G. Kees; Blom, Dirk J; Soran, Handrean; Watts, Gerald F; Lopez, J. Antonio G; Bray, Sarah; Kurtz, Christopher E; Hamer, Andrew W
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 18 nov. 2024.
APA
Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
NLM
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Vancouver
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Artigo de periodico
Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry (2020)
Pocock, Stuart J; Brieger, David; Gregson, John; Chen, Ji Y; Cohen, Mauricio G; Goodman, Shaun G; Granger, Christopher B; Grieve, Richard; Nicolau, José Carlos ; Simon, Tabassome
Source: Clinical cardiology. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, DOENÇAS CARDIOVASCULARES, FATORES DE RISCO, INCIDÊNCIA, ANÁLISE DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
POCOCK, Stuart J et al. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clinical cardiology, v. 43, n. 1, p. 24-32, 2020Tradução . . Disponível em: https://doi.org/10.1002/clc.23283. Acesso em: 18 nov. 2024.
APA
Pocock, S. J., Brieger, D., Gregson, J., Chen, J. Y., Cohen, M. G., Goodman, S. G., et al. (2020). Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. Clinical cardiology, 43( 1), 24-32. doi:10.1002/clc.23283
NLM
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry [Internet]. Clinical cardiology. 2020 ; 43( 1): 24-32.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1002/clc.23283
Vancouver
Pocock SJ, Brieger D, Gregson J, Chen JY, Cohen MG, Goodman SG, Granger CB, Grieve R, Nicolau JC, Simon T. Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry [Internet]. Clinical cardiology. 2020 ; 43( 1): 24-32.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1002/clc.23283
Artigo de periodico
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 (2020)
Furtado, Remo H. M; Nicolau, José Carlos ; Magnani, Giulia; Im, Kyungah; Bhatt, Deepak L; Storey, Robert F; Steg, P. Gabriel; Spinar, Jindrich; Budaj, Andrzej; Kontny, Frederic
Source: European heart journal. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, TERAPÊUTICA, RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European heart journal, v. 41, n. 17, p. 1625-+, 2020Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehz821. Acesso em: 18 nov. 2024.
APA
Furtado, R. H. M., Nicolau, J. C., Magnani, G., Im, K., Bhatt, D. L., Storey, R. F., et al. (2020). Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European heart journal, 41( 17), 1625-+. doi:10.1093/eurheartj/ehz821
NLM
Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 [Internet]. European heart journal. 2020 ; 41( 17): 1625-+.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1093/eurheartj/ehz821
Vancouver
Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54 [Internet]. European heart journal. 2020 ; 41( 17): 1625-+.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1093/eurheartj/ehz821
Artigo de periodico
Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries (2020)
Brieger, David; Pocockb, Stuart J; Blankenberg, Stefan; Chen, Ji Yan; Cohen, Mauricio G; Granger, Christopher B; Grieve, Richard; Nicolau, Jose Carlos ; Simon, Tabassome; Westermann, Dirk
Source: International journal of cardiology. Unidade: FM
Subjects: ENVELHECIMENTO, INFARTO DO MIOCÁRDIO, FATORES DE RISCO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRIEGER, David et al. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. International journal of cardiology, v. 311, p. 7-14, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ijcard.2020.01.070. Acesso em: 18 nov. 2024.
APA
Brieger, D., Pocockb, S. J., Blankenberg, S., Chen, J. Y., Cohen, M. G., Granger, C. B., et al. (2020). Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. International journal of cardiology, 311, 7-14. doi:10.1016/j.ijcard.2020.01.070
NLM
Brieger D, Pocockb SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries [Internet]. International journal of cardiology. 2020 ; 311 7-14.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.ijcard.2020.01.070
Vancouver
Brieger D, Pocockb SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries [Internet]. International journal of cardiology. 2020 ; 311 7-14.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.ijcard.2020.01.070
Artigo de periodico
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial (2020)
Furtado, Remo H. M; Venkateswaran, Ramkumar V; Nicolau, José Carlos ; Gurmu, Yared; Bhatt, Deepak L; Storey, Robert F; Steg, P. Gabriel; Magnani, Giuglia; Goto, Shinya; Dellborg, Mikael
Source: Journal of the american heart association. Unidade: FM
Subjects: CAFEÍNA, DISPNEIA, MORTALIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. Journal of the american heart association, v. 9, n. 10, 2020Tradução . . Disponível em: https://doi.org/10.1161/JAHA.119.015785. Acesso em: 18 nov. 2024.
APA
Furtado, R. H. M., Venkateswaran, R. V., Nicolau, J. C., Gurmu, Y., Bhatt, D. L., Storey, R. F., et al. (2020). Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. Journal of the american heart association, 9( 10). doi:10.1161/JAHA.119.015785
NLM
Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial [Internet]. Journal of the american heart association. 2020 ; 9( 10):[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/JAHA.119.015785
Vancouver
Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial [Internet]. Journal of the american heart association. 2020 ; 9( 10):[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/JAHA.119.015785
Artigo de periodico
Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF (2020)
Docherty, Kieran F; Jhund, Pardeep S; Anand, Inder; Bengtsson, Olof; Bohm, Michael; Boer, Rudolf A. de; Demets, David L; Desai, Akshay S; Drozdz, Jaroslaw; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: ENVELHECIMENTO, MÉTODO DUPLO-CEGO, INSUFICIÊNCIA CARDÍACA, PACIENTES AMBULATORIAIS, ESTUDOS RETROSPECTIVOS, HEMODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, v. 142, n. 17, p. 1623-1632, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.120.047480. Acesso em: 18 nov. 2024.
APA
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Bohm, M., Boer, R. A. de, et al. (2020). Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, 142( 17), 1623-1632. doi:10.1161/CIRCULATIONAHA.120.047480
NLM
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Vancouver
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Artigo de periodico
Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference (2020)
Lindner, Gregor; Burdmann, Emmanuel de Almeida ; Clase, Catherine M; Hemmelgarn, Brenda R; Herzog, Charles A; Mlyszko, Jolanta; Nagahama, Masahiko; Pecoits-Filho, Roberto; Rafique, Zubaid; Rossignol, Patrick; Singer, Adam J
Source: European journal of emergency medicine. Unidade: FM
Subjects: NEFROPATIAS, POTÁSSIO, SISTEMA RENINA-ANGIOTENSINA, SERVIÇO HOSPITALAR DE EMERGÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LINDNER, Gregor et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. European journal of emergency medicine, v. 27, n. 5, p. 329-337, 2020Tradução . . Disponível em: https://doi.org/10.1097/MEJ.0000000000000691. Acesso em: 18 nov. 2024.
APA
Lindner, G., Burdmann, E. de A., Clase, C. M., Hemmelgarn, B. R., Herzog, C. A., Mlyszko, J., et al. (2020). Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. European journal of emergency medicine, 27( 5), 329-337. doi:10.1097/MEJ.0000000000000691
NLM
Lindner G, Burdmann E de A, Clase CM, Hemmelgarn BR, Herzog CA, Mlyszko J, Nagahama M, Pecoits-Filho R, Rafique Z, Rossignol P, Singer AJ. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference [Internet]. European journal of emergency medicine. 2020 ; 27( 5): 329-337.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1097/MEJ.0000000000000691
Vancouver
Lindner G, Burdmann E de A, Clase CM, Hemmelgarn BR, Herzog CA, Mlyszko J, Nagahama M, Pecoits-Filho R, Rafique Z, Rossignol P, Singer AJ. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference [Internet]. European journal of emergency medicine. 2020 ; 27( 5): 329-337.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1097/MEJ.0000000000000691
Artigo de periodico
Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial (2019)
Franchi, Francesco; James, Stefan K; Lakic, Tatevik Ghukasyan; Budaj, Andrzej J; Cornel, Jan H; Katus, Hugo A; Keltai, Matyas; Kontny, Frederic; Lewis, Basil S; Nicolau, José Carlos
Source: Journal of the american heart association. Unidade: FM
Subjects: DIABETES MELLITUS, INSUFICIÊNCIA RENAL CRÔNICA, SÍNDROME CORONARIANA AGUDA, AGREGAÇÃO PLAQUETÁRIA, ANTICOAGULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRANCHI, Francesco et al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the american heart association, v. 8, n. 6, 2019Tradução . . Disponível em: https://doi.org/10.1161/JAHA.118.011139. Acesso em: 18 nov. 2024.
APA
Franchi, F., James, S. K., Lakic, T. G., Budaj, A. J., Cornel, J. H., Katus, H. A., et al. (2019). Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the american heart association, 8( 6). doi:10.1161/JAHA.118.011139
NLM
Franchi F, James SK, Lakic TG, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Nicolau JC. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial [Internet]. Journal of the american heart association. 2019 ; 8( 6):[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/JAHA.118.011139
Vancouver
Franchi F, James SK, Lakic TG, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Nicolau JC. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial [Internet]. Journal of the american heart association. 2019 ; 8( 6):[citado 2024 nov. 18 ] Available from: https://doi.org/10.1161/JAHA.118.011139
Artigo de periodico
Ticagrelor in patients with stable coronary disease and diabetes (2019)
Steg, P. Gabriel; Bhatt, Deepak L; Simon, Tabassome; Fox, Kim; Mehta, Shamir R; Harrington, Robert A; Held, Claes; Andersson, Marielle; Himmelmann, Anders; Nicolau, José Carlos
Source: New england journal of medicine. Unidade: FM
Subjects: CORONARIOPATIA, DIABETES MELLITUS, ADENOSINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, P. Gabriel et al. Ticagrelor in patients with stable coronary disease and diabetes. New england journal of medicine, v. 381, n. 14, p. 1309-1320, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1908077. Acesso em: 18 nov. 2024.
APA
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., et al. (2019). Ticagrelor in patients with stable coronary disease and diabetes. New england journal of medicine, 381( 14), 1309-1320. doi:10.1056/NEJMoa1908077
NLM
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Nicolau JC. Ticagrelor in patients with stable coronary disease and diabetes [Internet]. New england journal of medicine. 2019 ; 381( 14): 1309-1320.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1056/NEJMoa1908077
Vancouver
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Nicolau JC. Ticagrelor in patients with stable coronary disease and diabetes [Internet]. New england journal of medicine. 2019 ; 381( 14): 1309-1320.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1056/NEJMoa1908077
Artigo de periodico
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (2019)
Mcmurray, J. J. V; Solomon, S. D; Inzucchi, S. E; Kober, L; Kosiborod, M. N; Martinez, F. A; Ponikowski, P; Sabatine, M. S; Anand, I. S; Nicolau, José Carlos
Source: New england journal of medicine. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, PROTEÍNAS DE TRANSPORTE, RESULTADO DE TRATAMENTO, ESTUDOS PROSPECTIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MCMURRAY, J. J. V et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, v. 381, n. 21, p. 1995-2008, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1911303. Acesso em: 18 nov. 2024.
APA
Mcmurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Martinez, F. A., et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New england journal of medicine, 381( 21), 1995-2008. doi:10.1056/NEJMoa1911303
NLM
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1056/NEJMoa1911303
Vancouver
Mcmurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Nicolau JC. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [Internet]. New england journal of medicine. 2019 ; 381( 21): 1995-2008.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1056/NEJMoa1911303

USP Schools

ReP

Filtros

Authors

Subjects

Source title

Funding Agencies